Home > Documents in Process > Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy. > print

001     282966
005     20251219150319.0
024 7 _ |a 10.1093/braincomms/fcaf467
|2 doi
024 7 _ |a pmid:41416250
|2 pmid
024 7 _ |a pmc:PMC12709281
|2 pmc
037 _ _ |a DZNE-2025-01418
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Shapiro, Noah L
|0 0000-0002-7786-2747
|b 0
245 _ _ |a Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy.
260 _ _ |a [Oxford]
|c 2025
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1766152894_31935
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Progressive supranuclear palsy (PSP) is a primary tauopathy characterized by atrophy and neuroinflammation of the brainstem, the basal ganglia and, to a lesser degree, the cortex. This study investigates the association of regional atrophy (structural MRI), neuroinflammation ([11C]-PK11195 PET), peripheral markers of neurodegeneration [plasma neurofilament light chain (NfL)] and clinical severity [PSP rating scale (PSPRS)] with survival in people with PSP. Fifty-nine people with PSP underwent longitudinal structural MRI, surviving on average 3.2 years from the first scan (MRI cohort). Sixteen participants (PET cohort) within this cohort underwent cross-sectional [11C]-PK11195 PET and blood sampling for plasma NfL. We applied modality-specific principal component analyses on imaging data and ran partial correlations, multivariate regressions and Bayesian models to evaluate the association between survival and imaging patterns, clinical severity and plasma NfL. In the PET cohort, higher levels of localized inflammation in subcortical regions [rho = -0.49, P = 0.02, Bayes factor (BF) = 8.07] and plasma NfL (rho = -0.57, P = 0.01, BF = 4.63) were associated with shorter survival, while PSPRS scores were not significant predictors of survival. Subcortical atrophy was associated with shorter survival in the larger cohort (r = -0.38, P = 0.001; β = -0.66, P = 0.001). Spearman's correlations, multivariate regressions and Bayesian models converged to the same results. Regional subcortical atrophy is a robust biomarker associated with survival in people with PSP that can be utilized in large-scale clinical trials. Translocator protein (TSPO) PET and plasma NfL offer promising complementary markers for smaller-scale trials, where they may prove more sensitive than clinical scores or structural MRI alone. By linking neuroinflammation to survival, our results also highlight immunotherapy as a promising avenue for disease-modifying treatment in PSP.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a PET NfL
|2 Other
650 _ 7 |a neuroinflammation
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
650 _ 7 |a survival
|2 Other
700 1 _ |a Jones, Peter Simon
|b 1
700 1 _ |a Mak, Elijah
|0 0000-0002-6437-8024
|b 2
700 1 _ |a Tsvetanov, Kamen A
|b 3
700 1 _ |a Goddard, Julia
|b 4
700 1 _ |a Vontobel, Davi S
|b 5
700 1 _ |a Durcan, Robert
|0 0000-0001-9870-0117
|b 6
700 1 _ |a Chouliaras, Leonidas
|0 0000-0002-3052-3879
|b 7
700 1 _ |a Fryer, Tim
|b 8
700 1 _ |a Hong, Young T
|b 9
700 1 _ |a Aigbirhio, Franklin
|b 10
700 1 _ |a Heslegrave, Amanda
|b 11
700 1 _ |a Franzmeier, Nicolai
|0 0000-0001-9736-2283
|b 12
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 13
700 1 _ |a Zetterberg, Henrik
|b 14
700 1 _ |a O'Brien, John T
|0 0000-0002-0837-5080
|b 15
700 1 _ |a Rowe, James B
|b 16
700 1 _ |a Malpetti, Maura
|0 0000-0001-8923-9656
|b 17
773 _ _ |a 10.1093/braincomms/fcaf467
|g Vol. 7, no. 6, p. fcaf467
|0 PERI:(DE-600)3020013-1
|n 6
|p fcaf467
|t Brain communications
|v 7
|y 2025
|x 2632-1297
856 4 _ |u https://pub.dzne.de/record/282966/files/DZNE-2025-01418.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/282966/files/DZNE-2025-01418.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN COMMUN : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-03T10:36:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-03T10:36:45Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-03T10:36:45Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-04-03T10:36:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-20
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-20
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21